Developer docs
API playgroundTry for free, no card

Search company profiles

Illumina Accelerator

Full company profile

uuid0007hph

Namestring
Illumina Accelerator
Legal namestring
Illumina, Inc.
Websiteurl
illumina.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Illumina, Inc. (NASDAQ: ILMN) is a publicly traded Delaware-incorporated corporation headquartered at 5200 Illumina Way, San Diego, that develops next-generation sequencing (NGS) and microarray technologies for genomic analysis. The company's product portfolio spans benchtop-to-production-scale sequencing platforms (MiSeq i100, NextSeq 1000/2000, NovaSeq 6000, NovaSeq X Series), microarray scanners and Infinium arrays, library preparation kits (Illumina DNA Prep, AmpliSeq, Stranded mRNA Prep, Single Cell 3' RNA Prep), and IVD instruments and assays (MiSeqDx, NextSeq 550Dx, VeriSeq NIPT, TruSight Oncology). The technology stack is complemented by a software layer that includes BaseSpace Sequence Hub for cloud data management, DRAGEN for hardware-accelerated secondary analysis, Illumina Connected Analytics/Multiomics/Insights for downstream interpretation, Emedgene for AI-driven variant analysis, and Clarity LIMS for laboratory workflow management.

Illumina operates a multi-channel commercial model combining direct enterprise field sales, inside sales, a global distributor network (including a regional office in Seoul, South Korea), and the MyIllumina e-commerce platform. Revenue is generated through four primary streams: one-time hardware sales of sequencing platforms and microarray scanners, recurring revenue from kits and reagents tied to instrument utilization, software subscriptions and licenses for cloud and on-premise informatics products, and professional services including sequencing services, microarray services, training, and proactive instrument monitoring. Pricing is quote-based and not publicly disclosed, with financing solutions offered to support instrument purchases. The customer base spans oncology research and clinical applications, genetic and rare disease research, reproductive health, microbiology and infectious disease, agrigenomics, and complex disease and population genomics — serving academic research institutions, pharmaceutical companies, clinical laboratories, and commercial agriculture operations globally.

Illumina Accelerator is referenced as a startup accelerator program operated under Illumina, Inc. as part of the parent company's startup ecosystem initiatives; the input data does not provide program-level financials or cohort details. Source data attributes partnerships with IDbyDNA (NGS infectious disease solutions) and Harvard Pilgrim Health Care (value-based NIPT) as core strategic alliances, and notes an active product cadence including the 2026 NovaSeq X Series Software v1.4 and DRAGEN v4.5 release, the Illumina 5-base Solution, and StrataMap Spatial transcriptomics.

Short descriptiontext

Illumina, Inc. (NASDAQ: ILMN) develops next-generation sequencing platforms, microarray technologies, library prep kits, and bioinformatics software for genomics research, clinical diagnostics, and applied markets including oncology, rare disease, reproductive health, microbiology, and agrigenomics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic sequencing platforms, sequencing reagents kits, bioinformatics analytics software, microarray genotyping solutions, genomic data services
Industry3 codes
PRIMARYBPAEAHAK
Industry/Domain Analytics Solutions & Accelerators
SECONDARYBPAEAHAF
AI/ML Engineering & Model Development Services
SECONDARYHDAEANAH
Enterprise AI Data & Knowledge Platforms (Vector Databases, Knowledge Graphs)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise
NAICS code2 codes
  • Computer Systems Design and Related Services54151
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services518210
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Optical Instruments & Lenses3827
Product category
Genomic Sequencing Instruments and Consumables
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Sequencing Platforms and Instruments
TypeHardware Sales
Description

Sale of NGS sequencing platforms ranging from benchtop to production scale systems including NovaSeq X Plus, NextSeq 1000/2000, MiSeq, and microarray scanners. Revenue from one-time hardware sales with ongoing reagent and service requirements.

illumina.com:443
2Kits and Reagents
TypeUsage Based
Description

Recurring revenue from library preparation kits, sequencing reagents, microarray kits, and clinical research products. Consumables represent recurring revenue tied to instrument utilization.

illumina.com:443
3Software Subscriptions and Licenses
TypeSubscription Recurring
Description

Cloud-based and on-premise software solutions including BaseSpace Sequence Hub, DRAGEN, Illumina Connected Analytics, and Clarity LIMS offered through subscription or perpetual licensing models.

illumina.com:443
4Services and Support
TypeProfessional Services
Description

Instrument services, training, proactive monitoring, sequencing services, and microarray services provided to customers.

illumina.com:443
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 18 records shown
1BaseSpace Sequence Hub
Description

Cloud-based sequencing data analysis platform and software solution

illumina.com:443
+17 more records
Core offering1 text field

Illumina, Inc. (NASDAQ: ILMN) develops, manufactures, and sells next-generation sequencing (NGS) and microarray-based systems, including benchtop and production-scale sequencers (e.g., NextSeq 2000, MiSeq i100 Series, NovaSeq X), along with associated reagents, library prep kits, microarray consumables, bioinformatics software (Illumina Connected Software/Analytics/Insights), and professional services. The Illumina Accelerator is a startup accelerator program that funds and mentors genomics entrepreneurs building breakthrough applications using Illumina's technology platforms.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Illumina offers a comprehensive genomic ecosystem comprising sequencing platforms ranging from benchtop (MiSeq i100 Series) to production scale (NovaSeq X Series, NovaSeq 6000, NextSeq 1000 & 2000), complemented by a full suite of library preparation kits (Illumina DNA Prep, Illumina Stranded mRNA Prep, AmpliSeq, Single Cell 3' RNA Prep) and microarray solutions (Infinium Arrays). The software portfolio centers on BaseSpace Sequence Hub as the cloud data management platform, with DRAGEN for accelerated secondary analysis, and Connected Analytics/Multiomics/Insights for downstream data interpretation and clinical applications. Specialized solutions include TruSight Oncology for cancer testing, TruPath Genome for whole genome sequencing, and Illumina 5-base for combined genetic and epigenetic analysis. The company also provides IVD instruments (MiSeqDx, NextSeq 550Dx) and services including sequencing, microarray, and instrument monitoring. Illumina's technology spans next-generation sequencing, microarray technology, and multiomics integration across genomics, transcriptomics, proteomics, and epigenomics applications.

Product and service25 records
1NextSeq 2000
CategorySequencing instrument
Description

Production-scale next-generation sequencing platform for exomes, transcriptomes, and whole genomes across a broad range of sample types.

2MiSeq i100 Series
CategorySequencing instrument
Description

Benchtop NGS system designed for low-throughput sequencing runs, including targeted panels, amplicon sequencing, small genomes, and 16S metagenomics.

3MiSeq i100 Plus
CategorySequencing instrument
Description

Higher-output benchtop sequencer in the MiSeq i100 family for low- to mid-throughput sequencing applications.

4NextSeq 1000
CategorySequencing instrument
Description

Mid-throughput NGS platform with P1 and P2 flow cell configurations for a broad range of sequencing applications.

5NextSeq 2000 P4
CategorySequencing instrument
Description

Higher-throughput configuration of the NextSeq 2000 with P4 flow cells for larger sequencing projects.

6NextSeq 1000 P1
CategorySequencing instrument
Description

Entry-level flow cell configuration of the NextSeq 1000 sequencing platform.

7NovaSeq X
CategorySequencing instrument
Description

Production-scale sequencing platform delivering high-throughput NGS for large studies and population genomics.

8NovaSeq X Plus
CategorySequencing instrument
Description

Higher-throughput NovaSeq X configuration for very large-scale sequencing projects.

9NovaSeq X 25B
CategorySequencing consumable
Description

High-output flow cell configuration for the NovaSeq X series.

10NovaSeq X 10B
CategorySequencing consumable
Description

Mid-output flow cell configuration for the NovaSeq X series.

11NovaSeq X 1.5B
CategorySequencing consumable
Description

Lower-output flow cell configuration for the NovaSeq X series.

12iSeq 100
CategorySequencing instrument
Description

Low-throughput benchtop sequencer for targeted and small-scale NGS applications.

13MiSeq
CategorySequencing instrument
Description

Long-running benchtop NGS platform for small genomes, amplicons, and targeted resequencing.

14NextSeq 550
CategorySequencing instrument
Description

Mid-throughput sequencing and array scanner instrument used for sequencing and cytogenetic analysis.

15NextSeq 2000 Dx
CategoryDiagnostic sequencing instrument
Description

IVD-version of the NextSeq 2000 sequencer for clinical diagnostic use.

16NextSeq 550Dx
CategoryDiagnostic sequencing instrument
Description

IVD-version of the NextSeq 550 intended for clinical and diagnostic laboratory workflows.

17iScan
CategoryMicroarray instrument
Description

Microarray scanner used with the Infinium family of genotyping and cytogenetic assays.

18Infinium Microarray Solutions
CategoryMicroarray products
Description

Family of microarray-based assays for genotyping, cytogenetics, and methylation analysis used on the iScan system.

19Illumina Connected Software
CategoryBioinformatics software
Description

Suite of bioinformatics software including BaseSpace Sequence Hub and related tools for run planning, analysis, and data management.

20Illumina Connected Analytics
CategoryBioinformatics software
Description

Cloud-based analytics environment for processing and interpreting NGS data at scale.

21Illumina Connected Insights
CategoryBioinformatics software
Description

Software suite supporting variant interpretation and genomic insights for clinical and translational workflows.

22Illumina Proactive
CategoryInstrument services
Description

Instrument performance monitoring service that enables remote support and uptime optimization for sequencing systems.

23Illumina Professional Services
CategoryProfessional services
Description

Consulting and expert services supporting sequencing program design, lab setup, and data interpretation.

24Illumina Training
CategoryTraining services
Description

Educational and certification programs that train scientists and lab staff on Illumina sequencing and analysis workflows.

25Illumina Accelerator
CategoryStartup accelerator program
Description

Startup accelerator program operated by Illumina that invests in and mentors genomics entrepreneurs building applications on Illumina technology; typically concludes with a public pitch event.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1IDbyDNA
Strategic tierCoreTypeTechnology or Integration
Description

Partnership to deliver NGS infectious disease solutions combining Illumina sequencing technology with IDbyDNA's advanced molecular diagnostics capabilities for comprehensive pathogen detection and characterization.

illumina.com:443
Strategic tierCoreTypeStrategic or Co-development Partner
Description

First NGS agreement for Non-Invasive Prenatal Testing (NIPT) establishing value-based healthcare partnership for genomic testing services.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Life sciences tools provider with droplet digital PCR, qPCR, and clinical diagnostics; overlaps with Illumina in research instruments and selected clinical applications.

TypeBroad incumbent
Description

Largest life sciences tools company offering sequencing (Ion Torrent), reagents, qPCR, and clinical diagnostics instruments. Competes with Illumina across reagents, instruments, and clinical genomics, though Illumina remains the NGS leader.

TypeDirect peer
Description

Long-read sequencing platform (Revio, Sequel II) increasingly competing in whole-genome, clinical, and complex-genome applications where Illumina's short reads have limitations.

TypeDirect peer
Description

Nanopore-based long-read sequencing (MinION, PromethION) competing across research and clinical genomics; a credible alternative for applications requiring long reads or rapid in-field sequencing.

TypeDirect peer
Description

Chinese genomics conglomerate offering DNBSEQ sequencing platforms and reagents at lower price points; competes globally on cost and is the primary IP-dispute counterpart to Illumina.

TypeDirect peer
Description

Single-cell and spatial genomics company (Chromium, Visium/Xenium); partners with Illumina sequencers and increasingly competes for high-value multi-omics and spatial workflows now addressed by StrataMap Spatial.

TypeBroad incumbent
Description

Sample-prep, molecular diagnostics, and bioinformatics provider; overlaps with Illumina on nucleic acid extraction, library prep reagents, and clinical bioinformatics.

TypeBroad incumbent
Description

Diagnostics giant with a growing NGS and digital PCR portfolio (KAPA reagents, AVENIO ctDNA, Navify); overlaps with Illumina in clinical oncology and reproductive health.

TypeBroad incumbent
Description

Diversified life sciences conglomerate owning Beckman Coulter, Cepheid, Leica, and IDT — competing with Illumina across reagents, sample prep, and diagnostics-adjacent workflows.

TypeBroad incumbent
Description

Life sciences and diagnostics company offering microarrays, NGS target enrichment (SureSelect), and bioinformatics; competes with Illumina in microarrays and selected sequencing workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment41 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Illumina Accelerator

Genomic Sequencing Instruments and Consumablesillumina.com

Illumina, Inc. (NASDAQ: ILMN) develops next-generation sequencing platforms, microarray technologies, library prep kits, and bioinformatics software for genomics research, clinical diagnostics, and applied markets including oncology, rare disease, reproductive health, microbiology, and agrigenomics.

What Illumina Accelerator does

Illumina, Inc. (NASDAQ: ILMN) is a publicly traded Delaware-incorporated corporation headquartered at 5200 Illumina Way, San Diego, that develops next-generation sequencing (NGS) and microarray technologies for genomic analysis. The company's product portfolio spans benchtop-to-production-scale sequencing platforms (MiSeq i100, NextSeq 1000/2000, NovaSeq 6000, NovaSeq X Series), microarray scanners and Infinium arrays, library preparation kits (Illumina DNA Prep, AmpliSeq, Stranded mRNA Prep, Single Cell 3' RNA Prep), and IVD instruments and assays (MiSeqDx, NextSeq 550Dx, VeriSeq NIPT, TruSight Oncology). The technology stack is complemented by a software layer that includes BaseSpace Sequence Hub for cloud data management, DRAGEN for hardware-accelerated secondary analysis, Illumina Connected Analytics/Multiomics/Insights for downstream interpretation, Emedgene for AI-driven variant analysis, and Clarity LIMS for laboratory workflow management.

Illumina operates a multi-channel commercial model combining direct enterprise field sales, inside sales, a global distributor network (including a regional office in Seoul, South Korea), and the MyIllumina e-commerce platform. Revenue is generated through four primary streams: one-time hardware sales of sequencing platforms and microarray scanners, recurring revenue from kits and reagents tied to instrument utilization, software subscriptions and licenses for cloud and on-premise informatics products, and professional services including sequencing services, microarray services, training, and proactive instrument monitoring. Pricing is quote-based and not publicly disclosed, with financing solutions offered to support instrument purchases. The customer base spans oncology research and clinical applications, genetic and rare disease research, reproductive health, microbiology and infectious disease, agrigenomics, and complex disease and population genomics — serving academic research institutions, pharmaceutical companies, clinical laboratories, and commercial agriculture operations globally.

Illumina Accelerator is referenced as a startup accelerator program operated under Illumina, Inc. as part of the parent company's startup ecosystem initiatives; the input data does not provide program-level financials or cohort details. Source data attributes partnerships with IDbyDNA (NGS infectious disease solutions) and Harvard Pilgrim Health Care (value-based NIPT) as core strategic alliances, and notes an active product cadence including the 2026 NovaSeq X Series Software v1.4 and DRAGEN v4.5 release, the Illumina 5-base Solution, and StrataMap Spatial transcriptomics.

Illumina Accelerator firmographics

Firmographics
Name
Illumina Accelerator
Legal name
Illumina, Inc.
Website
https://illumina.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Illumina, Inc. (NASDAQ: ILMN) develops next-generation sequencing platforms, microarray technologies, library prep kits, and bioinformatics software for genomics research, clinical diagnostics, and applied markets including oncology, rare disease, reproductive health, microbiology, and agrigenomics.
Ownership category
akta.pro rank

Illumina Accelerator industry classification

Industry
Product category
Genomic Sequencing Instruments and Consumables
NAICS
Computer Systems Design and Related Services (54151), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518210)
SIC
Laboratory Analytical Instruments (3826), Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYBPAEAHAK
Industry/Domain Analytics Solutions & Accelerators
SECONDARYBPAEAHAF
AI/ML Engineering & Model Development Services
SECONDARYHDAEANAH
Enterprise AI Data & Knowledge Platforms (Vector Databases, Knowledge Graphs)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise

Keywords

  • Genomic sequencing platforms
  • Sequencing reagents kits
  • Bioinformatics analytics software
  • Microarray genotyping solutions
  • Genomic data services

Where Illumina Accelerator is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Illumina Accelerator business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Sequencing Platforms and Instruments: Sale of NGS sequencing platforms ranging from benchtop to production scale systems including NovaSeq X Plus, NextSeq 1000/2000, MiSeq, and microarray scanners. Revenue from one-time hardware sales with ongoing reagent and service requirements.
  2. Kits and Reagents: Recurring revenue from library preparation kits, sequencing reagents, microarray kits, and clinical research products. Consumables represent recurring revenue tied to instrument utilization.
  3. Software Subscriptions and Licenses: Cloud-based and on-premise software solutions including BaseSpace Sequence Hub, DRAGEN, Illumina Connected Analytics, and Clarity LIMS offered through subscription or perpetual licensing models.
  4. Services and Support: Instrument services, training, proactive monitoring, sequencing services, and microarray services provided to customers.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Illumina Accelerator product offering

Product offering

Core offering

Illumina, Inc. (NASDAQ: ILMN) develops, manufactures, and sells next-generation sequencing (NGS) and microarray-based systems, including benchtop and production-scale sequencers (e.g., NextSeq 2000, MiSeq i100 Series, NovaSeq X), along with associated reagents, library prep kits, microarray consumables, bioinformatics software (Illumina Connected Software/Analytics/Insights), and professional services. The Illumina Accelerator is a startup accelerator program that funds and mentors genomics entrepreneurs building breakthrough applications using Illumina's technology platforms.

Product overview

Illumina offers a comprehensive genomic ecosystem comprising sequencing platforms ranging from benchtop (MiSeq i100 Series) to production scale (NovaSeq X Series, NovaSeq 6000, NextSeq 1000 & 2000), complemented by a full suite of library preparation kits (Illumina DNA Prep, Illumina Stranded mRNA Prep, AmpliSeq, Single Cell 3' RNA Prep) and microarray solutions (Infinium Arrays). The software portfolio centers on BaseSpace Sequence Hub as the cloud data management platform, with DRAGEN for accelerated secondary analysis, and Connected Analytics/Multiomics/Insights for downstream data interpretation and clinical applications. Specialized solutions include TruSight Oncology for cancer testing, TruPath Genome for whole genome sequencing, and Illumina 5-base for combined genetic and epigenetic analysis. The company also provides IVD instruments (MiSeqDx, NextSeq 550Dx) and services including sequencing, microarray, and instrument monitoring. Illumina's technology spans next-generation sequencing, microarray technology, and multiomics integration across genomics, transcriptomics, proteomics, and epigenomics applications.

Differentiator

Problem solved

Functional benefit

Brands

  • BaseSpace Sequence Hub: Cloud-based sequencing data analysis platform and software solution
  • DRAGEN Secondary Analysis
  • Illumina Connected Analytics
  • Illumina Connected Multiomics
  • Illumina Connected Insights
  • Emedgene
  • Clarity LIMS
  • Infinium Arrays
  • AmpliSeq for Illumina
  • Illumina DNA Prep
  • NovaSeq X Series
  • NextSeq 1000 and 2000
  • TruSight Oncology
  • VeriSeq NIPT Solution
  • iHope
  • Illumina 5-base Solution
  • Illumina StrataMap Spatial
  • TruPath Genome Solution

Products and services

  • NextSeq 2000 Production-scale next-generation sequencing platform for exomes, transcriptomes, and whole genomes across a broad range of sample types.
  • MiSeq i100 Series Benchtop NGS system designed for low-throughput sequencing runs, including targeted panels, amplicon sequencing, small genomes, and 16S metagenomics.
  • MiSeq i100 Plus Higher-output benchtop sequencer in the MiSeq i100 family for low- to mid-throughput sequencing applications.
  • NextSeq 1000 Mid-throughput NGS platform with P1 and P2 flow cell configurations for a broad range of sequencing applications.
  • NextSeq 2000 P4 Higher-throughput configuration of the NextSeq 2000 with P4 flow cells for larger sequencing projects.
  • NextSeq 1000 P1 Entry-level flow cell configuration of the NextSeq 1000 sequencing platform.
  • NovaSeq X Production-scale sequencing platform delivering high-throughput NGS for large studies and population genomics.
  • NovaSeq X Plus Higher-throughput NovaSeq X configuration for very large-scale sequencing projects.
  • NovaSeq X 25B High-output flow cell configuration for the NovaSeq X series.
  • NovaSeq X 10B Mid-output flow cell configuration for the NovaSeq X series.
  • NovaSeq X 1.5B Lower-output flow cell configuration for the NovaSeq X series.
  • iSeq 100 Low-throughput benchtop sequencer for targeted and small-scale NGS applications.
  • MiSeq Long-running benchtop NGS platform for small genomes, amplicons, and targeted resequencing.
  • NextSeq 550 Mid-throughput sequencing and array scanner instrument used for sequencing and cytogenetic analysis.
  • NextSeq 2000 Dx IVD-version of the NextSeq 2000 sequencer for clinical diagnostic use.
  • NextSeq 550Dx IVD-version of the NextSeq 550 intended for clinical and diagnostic laboratory workflows.
  • iScan Microarray scanner used with the Infinium family of genotyping and cytogenetic assays.
  • Infinium Microarray Solutions Family of microarray-based assays for genotyping, cytogenetics, and methylation analysis used on the iScan system.
  • Illumina Connected Software Suite of bioinformatics software including BaseSpace Sequence Hub and related tools for run planning, analysis, and data management.
  • Illumina Connected Analytics Cloud-based analytics environment for processing and interpreting NGS data at scale.
  • Illumina Connected Insights Software suite supporting variant interpretation and genomic insights for clinical and translational workflows.
  • Illumina Proactive Instrument performance monitoring service that enables remote support and uptime optimization for sequencing systems.
  • Illumina Professional Services Consulting and expert services supporting sequencing program design, lab setup, and data interpretation.
  • Illumina Training Educational and certification programs that train scientists and lab staff on Illumina sequencing and analysis workflows.
  • Illumina Accelerator Startup accelerator program operated by Illumina that invests in and mentors genomics entrepreneurs building applications on Illumina technology; typically concludes with a public pitch event.

Companies that use Illumina Accelerator

Customer profile

Segments6 records

Ideal customer profiles4 records

Illumina Accelerator technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Illumina Accelerator partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • IDbyDNAcoreTechnology or IntegrationPartnership to deliver NGS infectious disease solutions combining Illumina sequencing technology with IDbyDNA's advanced molecular diagnostics capabilities for comprehensive pathogen detection and characterization.
  • Harvard Pilgrim Health CarecoreStrategic or Co-development PartnerFirst NGS agreement for Non-Invasive Prenatal Testing (NIPT) establishing value-based healthcare partnership for genomic testing services.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Illumina Accelerator competitors and assessment

Company assessment

Broad incumbents

  • Bio-Rad Laboratories: Life sciences tools provider with droplet digital PCR, qPCR, and clinical diagnostics; overlaps with Illumina in research instruments and selected clinical applications.
  • Thermo Fisher Scientific: Largest life sciences tools company offering sequencing (Ion Torrent), reagents, qPCR, and clinical diagnostics instruments. Competes with Illumina across reagents, instruments, and clinical genomics, though Illumina remains the NGS leader.
  • Qiagen: Sample-prep, molecular diagnostics, and bioinformatics provider; overlaps with Illumina on nucleic acid extraction, library prep reagents, and clinical bioinformatics.
  • Roche: Diagnostics giant with a growing NGS and digital PCR portfolio (KAPA reagents, AVENIO ctDNA, Navify); overlaps with Illumina in clinical oncology and reproductive health.
  • Danaher: Diversified life sciences conglomerate owning Beckman Coulter, Cepheid, Leica, and IDT — competing with Illumina across reagents, sample prep, and diagnostics-adjacent workflows.
  • Agilent Technologies: Life sciences and diagnostics company offering microarrays, NGS target enrichment (SureSelect), and bioinformatics; competes with Illumina in microarrays and selected sequencing workflows.

Direct peers

  • Pacific Biosciences: Long-read sequencing platform (Revio, Sequel II) increasingly competing in whole-genome, clinical, and complex-genome applications where Illumina's short reads have limitations.
  • Oxford Nanopore Technologies: Nanopore-based long-read sequencing (MinION, PromethION) competing across research and clinical genomics; a credible alternative for applications requiring long reads or rapid in-field sequencing.
  • BGI Group / MGI Tech: Chinese genomics conglomerate offering DNBSEQ sequencing platforms and reagents at lower price points; competes globally on cost and is the primary IP-dispute counterpart to Illumina.
  • 10x Genomics: Single-cell and spatial genomics company (Chromium, Visium/Xenium); partners with Illumina sequencers and increasingly competes for high-value multi-omics and spatial workflows now addressed by StrataMap Spatial.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Illumina Accelerator social profiles

Digital presence

Illumina Accelerator financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Illumina Accelerator leadership team

Management profile

Number of profiles

Illumina Accelerator funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Illumina Accelerator M&A and investment

M&A and investment

M&A

Investments41 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Illumina Accelerator

What does Illumina Accelerator do?

Illumina, Inc. (NASDAQ: ILMN) develops, manufactures, and sells next-generation sequencing (NGS) and microarray-based systems, including benchtop and production-scale sequencers (e.g., NextSeq 2000, MiSeq i100 Series, NovaSeq X), along with associated reagents, library prep kits, microarray consumables, bioinformatics software (Illumina Connected Software/Analytics/Insights), and professional services. The Illumina Accelerator is a startup accelerator program that funds and mentors genomics entrepreneurs building breakthrough applications using Illumina's technology platforms.

Is Illumina Accelerator a public or private company?

Illumina Accelerator is a public company. It is classified as public and is currently operating.

When was Illumina Accelerator founded?

Illumina Accelerator was founded in 2014. It employs 1 to 10 people.

Where is Illumina Accelerator based?

Illumina Accelerator is headquartered in San Francisco, United States, in the North America region.

How does Illumina Accelerator make money?

Four revenue lines are on record. Sequencing Platforms and Instruments are the primary driver. The others are kits and Reagents, software Subscriptions and Licenses and services and Support.

Who are Illumina Accelerator's main competitors?

Broad incumbents on record are Bio-Rad Laboratories, Thermo Fisher Scientific, Qiagen, Roche, Danaher and Agilent Technologies. Direct peers are Pacific Biosciences, Oxford Nanopore Technologies, BGI Group / MGI Tech and 10x Genomics.

Does Illumina Accelerator have an API?

No public API is recorded for Illumina Accelerator.

What industry is Illumina Accelerator in?

Illumina Accelerator's product category is Genomic Sequencing Instruments and Consumables. Its primary akta.pro industry code is BPAEAHAK, Industry/Domain Analytics Solutions & Accelerators, with a secondary code of BPAEAHAF, AI/ML Engineering & Model Development Services. Its NAICS code is 54151 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TrendHunter.comCertified Sequencing LaboratoriesJuno Bio, a women's health company focused on precision vaginal microbiome testing, has opened its first CLIA-certified sequencing laboratory in Oakland, California. The new facility enables the company to scale provider-led care and advance precision diagnostics, building on their original wellness test that sold over 20,000 units. The company has raised $3.8 million from investors including Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator to support this growth.PR NewswireJuno Bio Opens First CLIA-Certified Sequencing Lab Dedicated Entirely to Women's Health, Backed by Ada Ventures, Artesian, Illumina Accelerator, and Entrepreneur FirstJuno Bio has opened its first CLIA-certified sequencing lab dedicated entirely to women's health in Oakland, California, marking a major step in scaling provider-led care and advancing precision vaginal microbiome testing. To support this growth, the company raised $3.8 million in funding from Ada Ventures, Artesian, Illumina Accelerator, and Entrepreneur First. Juno Bio has sold more than 20,000 tests organically and launched a new clinically actionable test that analyzes approximately 10,000 bacteria and fungi along with four common STIs, with the test currently available in 46 states.Tech Funding NewsAda Ventures and Illumina Accelerator back Juno Bio's $3.8M round to scale vaginal microbiome testing — TFNJuno Bio has raised $3.8 million in seed funding from Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator to scale its precision vaginal microbiome testing platform. The Oakland-based startup simultaneously opened its first CLIA-certified sequencing lab dedicated entirely to women's health, enabling it to process tests internally rather than outsourcing. According to the company's clinical data, 67.5% of patients who later used its platform had previously been misdiagnosed, underdiagnosed, or overdiagnosed, and roughly half had co-infections that conventional testing missed.Tech.euJuno Bio secures $3.8M and opens first sequencing lab dedicated to women's healthJuno Bio raised $3.8 million and opened its first sequencing lab in Oakland, California, dedicated to women's health. The company's platform analyzes about 10,000 bacteria and fungi plus four STIs, and has sold over 20,000 tests organically. It aims to expand access to actionable vaginal microbiome testing.YahooJuno Bio Opens First CLIA-Certified Sequencing Lab Dedicated Entirely to Women's Health, Backed by Ada Ventures, Artesian, Illumina Accelerator, and Entrepreneur FirstJuno Bio opened its first CLIA-certified sequencing lab in Oakland, California, dedicated to women's health. The company raised $3.8 million from Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator. The lab supports a clinically actionable vaginal microbiome and STI test available in 46 states.PapermarkTop 10 Biotech Startup Accelerators in 2025This article presents a curated list of the top 10 biotech startup accelerators for 2025, detailing their investment sizes, program lengths, and specific focus areas such as genomics and synthetic biology. It provides strategic guidance for founders on selecting appropriate programs and optimizing pitch deck distribution using the Papermark platform. The content highlights key industry players like IndieBio, JLABS by Johnson & Johnson Innovation, and Illumina to illustrate the landscape of support available for early-stage life sciences ventures.Tech in AsiaExclusive: Indonesian biotech startup gets funding from global acceleratorIndonesian biotech startup Nusantics has received funding from Illumina Accelerator, a global business accelerator focusing on the genomics industry. The company will collaborate with Illumina to advance research on the human respiratory microbiome, building on its previous seed and Series A funding from East Ventures.Cambridge IndependentIllumina Accelerator Cambridge is officially opened by regional mayorIllumina Accelerator Cambridge held a delayed ribbon-cutting ceremony, marking its official opening after two years. The accelerator has launched 13 start-ups since July 2020, with the Cambridgeshire and Peterborough Combined Authority providing £100,000 in seed funding to up to 30 businesses over three years.DisruptafricaSA AI-based biotech startup BixBio raises funding from Illumina AcceleratorBixBio, a South African AI-based biotech startup, was selected as one of seven genomics companies for the third global funding cycle of the Illumina Accelerator. The startup will develop a beta version of its gene variant identification tool for market launch in Q2 next year, spending six months in the US.BioSpaceIllumina Accelerator Invests in Seven Genomics Startups for Third Global CycleIllumina selected seven genomics startups for its third global funding cycle, investing in four Cambridge and three San Francisco Bay Area companies. The startups come from six countries and will receive seed investment, access to Illumina sequencing systems, and lab space. Applications for the next cycle are due October 1, 2021.